Group 35774

The voice of AI, Data and Innovation

Group 35773

Brief About the Episode

What happens when medicine stops treating everyone the same?

In this episode of TeqTalk, Jas Kaur explores one of the most consequential shifts in modern medicine: the move from population-average protocols to patient-specific digital models that learn your individual biology in real time.

Over 500 million people with type 2 diabetes were told on diagnosis day they would manage this condition for life. Two peer-reviewed studies — one published in the New England Journal of Medicine — suggest that’s not a biological inevitability. It’s a personalization failure. And a digital twin just proved it.

Jas traces the concept from its origin — the 1970 Apollo 13 crisis, where NASA engineers simulated every repair option on the ground before sending a single instruction to astronauts 200,000 miles away — through to three live clinical programs in US hospitals delivering peer-reviewed results that most leaders in health systems and digital health haven’t fully processed yet.

The episode closes on the question nobody is asking loudly enough: when your digital twin predicts something you don’t want to know, who decides whether you see it? When it informs an insurer’s risk model, who protects you? When it gets something wrong, who is responsible? The technology is outpacing the governance frameworks built to govern it — and that gap is where the next decisions need to be made.

Key Learnings for Leaders

Medicine has been treating individuals as averages — and that was always a data problem, not a biology problem.

Two patients with the same diagnosis, same age, same starting weight, given identical protocols, can produce completely different outcomes. Medicine has known this for decades. It treated them the same anyway — because there was no scalable alternative. Digital twins change that. The Cleveland Clinic randomized trial is the clearest evidence yet: 71% remission versus 2.4% isn’t a marginal improvement. It’s proof that standard care was producing predictably average results for a predictable reason.

The “simulate before you act” principle is 56 years old — healthcare is just the last major domain to arrive at it.

NASA used it in 1970 to bring Apollo 13 home. GE and Siemens applied it to jet engine maintenance in the 1990s — reducing unplanned downtime by up to 50%. The core principle is identical: when the real system is too risky to experiment on directly, build a virtual version and test there first. Healthcare’s delay wasn’t conceptual — it was a data infrastructure and governance problem. That problem has narrowed enough that peer-reviewed clinical evidence now exists for sepsis, cardiac surgery, and metabolic disease simultaneously.

The clinical results are no longer the question. The data architecture and governance gap is.

Digital twins require clean, integrated, real-time patient data — and healthcare data infrastructure hasn’t fully solved fragmentation, interoperability, or governance at the level these models need. The distance between “the trial worked” and “we can deploy this responsibly at scale” is still largely a data architecture gap. Health systems that close it fastest will have a structural advantage that compounds over time. That gap — between what the technology can now do and what most organizations can actually deploy — is precisely where Teqfocus works. We build the data foundation, connect the clinical and operational data layers, and help health system leaders make the architecture decisions that make deployment possible. The organizations building those foundations now won’t be scrambling to catch up in 2027.

Each solved use case makes the next one cheaper, faster, and more accurate — this is one compounding revolution, not five separate breakthroughs.

The sepsis twin informs the cardiac twin. The metabolic twin lowers the cost of the next. Every new validated use case increases the training data quality, reduces the infrastructure cost of deployment, and builds the clinical trust needed to extend the approach to the next condition. The $4.5B market today tracking toward $101B by 2031 (MarketsandMarkets) understates the pace when compound effects are factored in. We are at the beginning of this shift, not the middle.

If your organization is investing in AI, data, or digital transformation — this is the healthcare conversation your leadership team needs to have.

Join our mailing list

Be the first to know when new episodes drop.

Subscribe to get fresh drops, exclusive guest insights, and key takeaways in your inbox.